Evolution and clinical translation of drug delivery nanomaterials

Basit Öğe Kaydı
dc.authoridAyça Bal Öztürk / 0000-0002-6502-528Xen_US
dc.authorscopusidAyça Bal Öztürk / 57062000100
dc.authorwosidAyça Bal Öztürk / M-4472-2018
dc.contributor.authorHassan, Shabir
dc.contributor.authorPrakash, Gyan
dc.contributor.authorBal Öztürk, Ayça
dc.contributor.authorSaghazadeh, Saghi
dc.contributor.authorSohail, Muhammad Farhan
dc.contributor.authorSeo, Jungmok
dc.contributor.authorKhademhosseini, Ali
dc.date.accessioned2020-08-30T20:08:07Z
dc.date.available2020-08-30T20:08:07Z
dc.date.issued2017
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Temel Bilimleri Bölümüen_US
dc.description.abstractWith the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterial-based drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rate and bio-distribution still exist, thus making their successful translation to clinical application very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review, the stress has been made on the evolution of nanomaterials that are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA). (C) 2017 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipNational Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148, R01EB024403]; Presidential Early Career Award for Scientists and Engineers (PECASE)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Cancer Institute of the National Institutes of Health Pathway to Independence [K99CA201603]; Swiss National Science Foundation (SNSF)Swiss National Science Foundation (SNSF); TUBITAK - TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Belgian American Educational Foundation (BAEF); King Baudouin Foundation (KBS)en_US
dc.description.sponsorshipThe authors acknowledge funding from the National Institutes of Health (AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148, R01EB024403) and the Presidential Early Career Award for Scientists and Engineers (PECASE). Y.S.Z. acknowledges the National Cancer Institute of the National Institutes of Health Pathway to Independence Award (K99CA201603). The authors further acknowledge funding from Swiss National Science Foundation (SNSF) to S.H., TUBITAK - Turkey to A.B.O., Henri Benedictus postdoctoral fellowship from Belgian American Educational Foundation (BAEF) and King Baudouin Foundation (KBS) to S.S.en_US
dc.identifier.citationHassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., … Khademhosseini, A. (2017). Evolution and clinical translation of drug delivery nanomaterials. Nano Today, 15, 91–106. https://doi.org/10.1016/j.nantod.2017.06.008en_US
dc.identifier.doi10.1016/j.nantod.2017.06.008en_US
dc.identifier.endpage106en_US
dc.identifier.issn1748-0132en_US
dc.identifier.issn1878-044Xen_US
dc.identifier.pmid29225665en_US
dc.identifier.scopus2-s2.0-85026632563en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage91en_US
dc.identifier.urihttps://doi.org/10.1016/j.nantod.2017.06.008
dc.identifier.urihttps://hdl.handle.net/20.500.12713/888
dc.identifier.volume15en_US
dc.identifier.wosWOS:000411546200011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorBal Öztürk, Ayçaen_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofNano Todayen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDrug Deliveryen_US
dc.subjectInorganic Nanomaterialen_US
dc.subjectPolymeric Nanomaterialen_US
dc.subjectLiposomesen_US
dc.subjectClinical Trialsen_US
dc.subjectFda Approvalen_US
dc.titleEvolution and clinical translation of drug delivery nanomaterialsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
H82.pdf
Boyut:
1.03 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Temel Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu